Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zelasudil by Redx Pharma for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Zelasudil is under clinical development by Redx Pharma and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Zelasudil by Redx Pharma for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Zelasudil is under clinical development by Redx Pharma and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
Zamaporvint by Redx Pharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Zamaporvint is under clinical development by Redx Pharma and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Zamaporvint by Redx Pharma for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Zamaporvint is under clinical development by Redx Pharma and currently in Phase II for Extrahepatic Bile Duct Cancer. According to...
Zamaporvint by Redx Pharma for Metastatic Colorectal Cancer: Likelihood of Approval
Zamaporvint is under clinical development by Redx Pharma and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Zamaporvint by Redx Pharma for Metastatic Biliary Tract Cancer: Likelihood of Approval
Zamaporvint is under clinical development by Redx Pharma and currently in Phase II for Metastatic Biliary Tract Cancer. According to...